Biotechnology & Medical Research
Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
Nov 24 (Reuters) - Nektar Therapeutics :Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs.Nektar Therapeutics - costs related to concluding co’s activities related to Bayer's phase 3 Amikacin Inhale clinical program under 2007 agreement.Nektar...
Nov 24 (Reuters) - KLARIA PHARMA HOLDING AB (PUBL) :Q3 NET SALES SEK 2.3 MILLION VERSUS SEK 0 MILLION YEAR AGO.Q3 LOSS AFTER TAX SEK 1.2 MILLION VERSUS LOSS SEK 3.2 MILLION YEAR AGO.
No related earnings announcements are currently scheduled within the next 7 days.